Close Menu

NEW YORK — Israeli hematology firm Scopio Labs said Wednesday that it has received US Food and Drug Administration 510(k) clearance for its X100 hematology imaging and analysis system and its Full Field Peripheral Blood Smear application.

According to Tel Aviv-based Scopio, the product uses digital imaging and AI to automate peripheral blood smear analysis, preclassifying 200 white blood cells, providing platelet pre-estimate, and enabling RBC morphology evaluation.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.